Follicular Lymphoma: Doing Nothing Is a Real Option, and It Doesn't Feel Like One to Her
A single patient with asymptomatic, low-burden follicular lymphoma who meets no criteria for treatment. The disagreement isn't about the survival evidence — both hematologists agree on it — it's about which of the same trial's real findings should guide her specific care.
E.W., a 62-year-old retired court reporter, found out she had follicular lymphoma the way many patients with indolent disease do: an incidental finding, in her case a mildly enlarged retroperitoneal lymph node seen on a CT scan ordered for unrelated back pain. Biopsy confirmed grade 1-2 follicular lymphoma, and serial imaging over the past four months has shown stable, non-bulky disease — no node over 3cm, no B symptoms, no cytopenias, no organ compromise. By the GELF criteria used to decide when treatment is actually warranted in this disease, she meets none of them.
The evidence behind watchful waiting in exactly her situation is real and long-standing: Ardeshna's randomized watch-and-wait trial found no overall survival difference between watching and treating asymptomatic, low-burden follicular lymphoma immediately. What it settles medically has settled nothing for her personally — she has said plainly, at every visit, that being told to wait and rescan feels less like reassurance than like being asked to sit with a cancer diagnosis and do nothing about it. The same trial did measure quality of life, and this is where the detail matters more than the headline: it randomized three ways, and the significant improvements in the Mental Adjustment to Cancer and Illness Coping Style scores at month 7 belonged to the rituximab maintenance arm — four weekly infusions followed by two years of maintenance. The induction-only arm, four weekly doses and then nothing, showed no quality-of-life improvement over watchful waiting at all. So the trial does contain an answer to her actual complaint, but it is attached to two years of infusions rather than to four weeks of them, and the cheap version of the intervention is the version the trial found didn't work for the thing she is asking about.
Hematology clinic, treatment discussion
She meets none of the GELF criteria — largest node 2.4cm, no B symptoms, no cytopenias, stable across four months of imaging — and Ardeshna's randomized data found no survival difference between watching and treating immediately in exactly that population. Starting therapy now means real drug exposure for a survival benefit the trial does not show.
I'd read that same trial further than its survival endpoint — quality of life at month 7 was a co-primary endpoint, not an afterthought. But I'll state the finding precisely, because the imprecise version has been getting quoted in this building for years: the significant gains on the Mental Adjustment to Cancer and Illness Coping Style scales were in the rituximab maintenance arm. Induction alone showed no quality-of-life benefit over watchful waiting.
Which cuts against the version of my own position I came in with. If we're treating her anxiety with rituximab on the strength of that trial, we are committing her to induction plus two years of maintenance, and we should say that out loud rather than offer four weekly doses and imply the trial supports it.
'No survival benefit' has been the whole conversation so far, but the trial we're both citing measured more than survival — dismissing its other findings isn't the same as following the evidence more carefully, it's following less of it.
Then the honest thing to put in front of her is the two-year commitment, not a softened version of it. And I'd add one finding from the trial's own long-term quality-of-life analysis that neither of you has mentioned: anxiety fell over time in both arms, and what actually predicted who stayed anxious was coping style, not treatment assignment — avoidant coping tracked with higher anxiety and worse quality of life regardless of which arm a patient was in. That doesn't mean her distress isn't real or that rituximab can't help it. It means a drug is not the only lever here, and offering her infusions as the answer to how she feels about surveillance may be aiming at the wrong mechanism.
Agreed: start single-agent rituximab, with continued surveillance imaging on the same schedule as before.
Not raised as a live disagreement in the end: whether combination chemoimmunotherapy might eventually be warranted if her disease burden increases — not part of today's decision, since nothing about her current, still-low-burden disease calls for it.